key: cord-0838562-o9uar3vv
authors: Kwon, Jaedeok; Suessmilch, Maria; McColl, Alison; Cavanagh, Jonathan; Morris, Brian J.
title: Distinct trans-placental effects of maternal immune activation by TLR3 and TLR7 agonists: implications for schizophrenia risk
date: 2021-09-21
journal: bioRxiv
DOI: 10.1101/2021.09.20.460754
sha: 1ca554c8c19fd83a9cb338e8c512a17556bc10f4
doc_id: 838562
cord_uid: o9uar3vv

Exposure to infection in utero predisposes towards psychiatric diseases such as autism, depression and schizophrenia in later life. The mechanisms involved are typically studied by administering mimetics of double-stranded (ds) RNA viral or bacterial infection to pregnant rats or mice. The effect of single-stranded (ss) virus mimetics has been largely ignored, despite evidence linking prenatal ss virus exposure specifically with psychiatric disease. Understanding the effects of gestational ss virus exposure has become even more important with the current SARS-CoV-2 pandemic. In this study, in pregnant mice, we compare directly the effects, on the maternal blood, placenta and the embryonic brain, of maternal administration of ds-virus mimetic poly I:C (to activate toll-like receptor 3, TLR3) and ss-virus mimetic resiquimod (to activate TLR7/8). We find that, 4h after the administration, both poly I:C and resiquimod elevated the levels of IL-6, TNFα, and chemokines including CCL2 and CCL5, in maternal plasma. Both agents also increased placental mRNA levels of IL-6 and IL-10, but only resiquimod increased placental TNFα mRNA. In foetal brain, poly I:C produced no detectable immune-response-related increases, whereas pronounced increases in cytokine (e.g. Il-6, Tnfα) and chemokine (e.g. Ccl2, Ccl5) expression were observed with maternal resiquimod administration. The data show substantial differences between the effect of maternal exposure to a TLR7/8 activator as compared to a TLR3 activator. There are significant implications for future modelling of diseases where maternal ss virus exposure contributes to environmental disease risk in offspring.

Maternal bacterial and viral infections during pregnancy increase the risk of psychiatric disease in the offspring exposed to the infection in utero. This is the case for autism spectrum disorders, major depressive disorder (Brown and Meyer, 2018; al-Haddad et al., 2019) and schizophrenia (Brown et al., 2001; Brown, 2006; Brown, 2012) . The mechanisms involved remain unclear, but are likely to involve the exposure of the developing foetal brain to either the infectious agent itself, or to cytokines and chemokines released from maternal or placental tissues as part of the innate immune response. Direct exposure of the developing foetal CNS to the infectious agent is possible, as the agents most strongly linked by epidemiological evidence to schizophrenia risk (rubella virus, influenza virus and the parasite Toxoplasma Gondii) (Brown et al., 2001; Brown, 2006; Mortensen et al., 2007; Brown, 2012) , are all able to penetrate the placenta to invade the foetal environment (Rasmussen et al., 2012; Leung et al., 2019; Ostrander and Bale, 2019) . Whatever the mechanism, the infectious agent or immune response molecules impact upon differentiating or migrating neurons e.g interneurons, and can affect microglia in the developing CNS with consequences for processes such as synaptic pruning . Exactly how these processes operate to raise risk of psychiatric disease remains uncertain.

Maternal immune activation models typically involve pregnant mice being injected with the bacterial mimetic lipopolysaccharide (LPS), or the double-stranded (ds) virus mimetic polyinosinic: polycytidylic acid (poly I:C). The consequences for the neurochemical and behavioural phenotype of the offspring can then be evaluated. A variety of disease-relevant changes in gene expression and social, affective and cognitive behaviours have been detected in offspring at various ages (Meyer et al., 2009; Meyer, 2014; Estes and McAllister, 2016) , although there have also been concerns about the reproducibility of some of the data with poly I:C, due to a variety of technical factors (e.g. batch variation, endotoxin contamination) (Kowash et al., 2019; Mueller et al., 2019) .

LPS reproduces the effects of bacterial infection by stimulating the toll-like receptor (TLR) TLR4, while poly I:C reproduces the effects of ds-virus infection by stimulating TLR3. Ss-viruses stimulate TLR7 or TLR8 to induce an immune response. However, despite the fact that some of the prenatal infectious agents most strongly linked to schizophrenia risk (rubella virus and influenza virus) are ss-viruses, models of maternal immune infection with ss-virus mimetics such as resiquimod or imiquimod, which stimulate TLR7/8 (Hemmi et al., 2002; Isobe et al., 2006) are rarer. Similarly, Toxoplasma Gondii also induces an innate immune response via TLR7 (Andrade et al., 2013; Yarovinsky, 2014) , while ds-viruses such as Herpes simplex II are not robustly linked to schizophrenia risk . Furthermore, some recent evidence in mice suggests that the behavioural consequences for offspring exposed to TLR7 stimulation in utero may be different to the effects of maternal TLR3 or TLR4 stimulant exposure (Missig et al., 2020) .

Our research question in this study was: what are the differences in the cytokine/chemokine responses to the commonly-used ds viral mimic versus ss viral mimic. We have directly compared the most commonly used strategy for studying the effects of MIA (poly I:C administration in mice) with a novel strategy using resiquimod to mimic ss-virus infection.

Poly I:C is frequently used in mice to model MIA. Concerns have been raised recently about variability in its effects, due partly to possible endotoxin contamination and batch variation (Kowash et al., 2019; Mueller et al., 2019) . The dose used is most commonly 20mg/kg, and the gestational time point is generally E9, E12.5 or E17, with E12.5 the most frequent choice, as it is argued to correspond in various ways to mid-gestation time in humans (Meyer et al., 2009; Meyer, 2014; Estes and McAllister, 2016; Brown and Meyer, 2018) . We used poly I:C of the specification that reportedly gives the most robust results (Kowash et al., 2019; Mueller et al., 2019) , and selected resiquimod as the ss-virus mimetic comparator. While imiquimod has recently been used to study the consequences for CNS function of ss-virus infection (Thomson et al., 2014; McColl et al., 2016) , and to assess the behavioural effects in offspring of MIA (Missig et al., 2020) , apart from acting as a ss-virus mimetic, imiquimod also has direct actions on adenosine receptors that complicate interpretation of its effects (Schön et al., 2006; Wolff et al., 2013) . In addition, imiquimod is selective for TLR7, whereas resiquimod activates both TLR7 and TLR8 (Patinote et al., 2020) . Considering that the epidemiological evidence for psychiatric disease risk implicates maternal ss-virus infection, without discriminating between TLR7 and TLR8 mediation, resiquimod seems to be the better choice to maximise construct validity in future models of environmental contribution to psychiatric disease risk.

Resiquimod has been used systemically in mice on occasion, producing an immune response at doses between 1 and 10 mg/kg (Su et al., 2005; Baenziger et al., 2009; Adzavon et al., 2017; Michaelis et al., 2019) . McAllister et al (McAllister et al., 2013) describe equivalent (and substantial) serum TNF responses to high doses of 30mg/kg poly I:C and 10 mg/kg resiquimod in mice. We therefore selected 2 mg/kg as a moderate dose of resiquimod to compare with the standard dose of 20mg/kg poly I:C.

Wild type mice (C57/BL6, female, aged wk4) were purchased from Envigo. Mice were time mated separated following day, and if the pregnancy was confirmed the day was given as E0. Female mice were weighed and monitored for 12 days. All mice were aged 7-9 weeks and weighed 30+/-1 g at the point of experiment (12.5 days pregnant). In order to induce maternal immune activation (MIA), three treatments, vehicle (PBS, 2 ml/kg, Gibco 14190144), poly I:C (20 mg/kg of a 10 mg/ml solution in PBS, LMW, Invivogen tlrl-picw), resiquimod (2 mg/kg of a 1 mg/ ml solution in PBS, Invivogen tlrl-r848), were administered subcutaneously on E12.5 between 9:00-11:00 am and their conditions were monitored to ensure that there was no sign of any severe sickness symptoms or abnormalities. 4 hours following injections, the pregnant dam was culled with the CO2 euthanasia. The maternal blood was collected via right atrium into an EDTA-coated syringe. The blood was injected into an EDTA-coated 1.5 micro centrifuge tube containing 100 ul EDTA and shaken. Experimental samples were collected. Following centrifugation at 10,000g at 4°C for 10 minutes, the supernatant (plasma) was frozen at -80°C for further use. Once the blood collection was done, cut right atrium and PBS perfusion was carried. After the PBS perfusion, maternal placentae and embryos were dissected and collected. All tissues were pre-processed and stored until further uses. More details of sample preparation procedures are described in separate sections. All experiments were reviewed by the University of Glasgow ethical committee and were performed under the authority of UK Home Office License.

Collected tissues after MIA experiment were originally stored in RNAlater at -80 C. Before extracting total RNA from the tissues, they had to be completely thawed in RT and RNAlater had to be removed. Under RNase-fee condition, the collected tissues were homogenised using the TissueLyser LT (Qiagen) in 600 l of prepared RLT lysis buffer (Qiagen). Total RNA was extracted from the stabilised tissues using an RNeasy mini kit (Qiagen, 79254) with additional DNase I (Qiagen, 79254) as per manufacturer's instruction. The RNA concentration was determined by a Nanodrop DeNovix DS-11+Spectrophotometer. RNA was reverse-transcribed to cDNA using Highcapacity RNA-to-cDNA TM kit (Applied Biosystems, 4387406) according to the manufacturer's instruction. cDNA concentration was normalised by using equal quantity of RNA.

Gene expression in the tissues was quantified Fast SybrGreen TM master mix (Applied Biosystems, 4385612) for each target using the QuantaStudio7 (Thermo Fisher Scientist). Samples were run in triplicate on 384 well qPCR plates (Applied Biosystems, 4309849) and the levels of the target genes were normalised to a geometric mean of two housekeeping genes (Gapdh, Tbp) and relative differences in target gene expression were determined using absolute quantification method. Primer sequences are provided in Supplementary Table 2 .

The concentration of 9 cytokines and chemokines with well-characterised roles in innate immune responses were measured in maternal plasma by a Multiplex/Luminex (Merck, MCYTMAG-70K-PX32) according to the manufacturer's instruction. Measurements were taken (LUMINEX 200 ® ), operated via Bio-Rad's Bio-Plex software version 6.1 TM . The beads were read determining the mean fluorescence intensity (MFI) (Breen et al., 2015; Breen et al., 2016; Richter et al., 2017) and the data were accepted if the duplicated samples vary (CoV) were less than 15%.

All statistical analyses were carried out using Minitab 19 Statistical Software and all data were reported as group mean ± S.E.M. Luminex data were Box-Cox transformed prior to one-way analysis of variance (ANOVA) with post hoc Fisher LSD tests to correct for multiple comparisons. Non-normally distributed RT-qPCR data were log transformed, followed by two-way ANOVA with post Tukey tests. A p-value of <0.05 was considered significant.

Following poly I:C and resiquimod there were increases in the levels of immune molecules in maternal plasma, compared to vehicle administration. Of the 9 cytokine/ chemokines tested, IL-6, TNF, IL-10, CCL2, CCL5, CXCL10, and LIF (leukaemia inhibitory factor) were all elevated following both poly I:C and resiquimod administration: (Figure 1 ). Maternal plasma from mice injected with resiquimod, but not poly I:C, also showed significantly upregulated CCL11 and CXCL1, (Figure 1 ). In general, the effects of poly I:C showed a greater variability in the magnitude of cytokine/chemokine induction, compared to resiquimod.

The data from maternal plasma clearly confirm that the experimental conditions caused an immune response in the dams. We next assessed the response of placental tissue to the immune stimuli, measuring mRNA levels so that changes detected can be unequivocally ascribed to the placenta, as opposed to maternal plasma.

Resiquimod administration elevated expression of most of inflammatory cytokine and chemokine mRNAs (Tnf-, Ccl5, Ccl11 and Cxcl1) without affecting Ccl2 and Cxcl12 mRNA levels ( Figure 2) . Table 1 Poly I:C induced Il-6, Il-10, and Cxcl10 mRNA levels, but changes were not observed in any other genes (Figure 2A , C, and H). While CCL2 in maternal plasma was significantly induced by both poly I:C and resiquimod injection ( Figure 1D ), placental Ccl2 mRNA was not changed by either MIA condition compared to vehicle ( Figure 2D ). Overall, the results suggest that while the response to poly I:C and resiquimod in maternal plasma is rather similar, the response of placental tissue to poly I:C is much more limited compared to the response to resiquimod. 

The same cytokines and chemokines mRNAs were measured in foetal brain tissue 4h after MIA ( Figure 3 ). Foetal brains from MIA caused by resiquimod showed significantly increased levels of most of cytokine and chemokine mRNAs compared to vehicle administration. However, the foetal brain tissue from poly I:C MIA did not show any induction of immune molecule genes.

There is considerable evidence for microglial activation in foetal brain following MIA with poly I:C (Smolders et al., 2015; Prins et al., 2018; Murray et al., 2019; Ozaki et al., 2020) . We tested possible altered expression of microglial markers in foetal brain tissue after MIA. The results showed that the expression of Aif1 (Iba-1) was significantly increased by resiquimod, but not by poly I:C ( Figure 4C ). In contrast, Tmem119 and Cx3cr1 mRNA levels were down regulated by resiquimod ( Figure 4A, B) . Noticeably, poly I:C caused a significant reduction in the levels of Tmem119 mRNA , but not Cx3cr1 mRNA. Ccr2 mRNA was decreased by both stimuli for MIA, although resiquimod's impact was greater than poly I:C ( Figure 4D ). Ly6c2 mRNA levels were not affected by MIA ( Figure 4E ).

In addition, due to its frequent link to environmental risk for psychiatric disease, we also monitored the expression of Bdnf. There were no changes in Bdnf expression in foetal brain, but resiquimod exposure decreased Bdnf mRNA levels in placenta (Supplementary figure1).

Foetal development is affected by sex (Thion et al., 2018; Gildawie et al., 2020) . In order to identify any sex-dependent influence on the foetal immune response, the embryos' sex was determined by qPCR, using the sex-specific Xist gene (Cheung et al., 2017) . High Xist expression indicated female and low expression male (Supplementary Figure2) , and suggested that the samples were wellbalanced for sex within a treatment group. No statistically significant interaction of sex with the effect of MIA was observed for any of the markers. 

This study provides a direct comparison of the pattern of immune response to poly I:C and resiquimod in maternal, placental and foetal brain compartments. It is clear that their patterns of immune activation are different, and the differences are important for future studies of MIA effects on offspring.

Maternal plasma showed evidence of a clear immune response to both poly I:C and resiquimod, with induction of cytokines, including Tnf and Il-6, and chemokines, including Ccl2 and Ccl5. Maternallyderived Il-6 acting on the placenta, but conceivably originating either in maternal plasma monocytes or in the placenta itself, has been viewed as a key component of MIA effects on the foetus (Hsiao and Patterson, 2011; Wu et al., 2017) . Hence the induction of maternal Il-6 observed here is potentially important for some of the downstream events we detect in the foetal brain. However, our data suggested that maternal plasma IL-6 levels were not correlated with mRNA level changes in placenta and embryo brain samples (data not shown). This suggests that the gene induction in placenta and embryo brain samples is less likely to be caused by maternal plasma IL-6.

At the doses used, however, resiquimod tended to produce larger effects than poly I:C. The variability of the maternal immune response to poly I:C in mice and rats has been highlighted recently ( The elevated plasma levels of LIF after exposure to either poly I:C or resiquimod are notable, since maternal LIF is linked to the trans-placental control of foetal neurogenesis (Wright et al., 2006; Simamura et al., 2010) , and to the modulation of foetal responses to elevated maternal glucocorticoids (Ware et al., 2003) . Induction of maternal LIF may be important for the effects of MIA on foetal brain development and psychiatric disease risk.

In previous MIA studies, maternal LPS administration elevated amniotic fluid Tnf and IL-6 protein after 4h (Oskvig et al., 2012) . Poly I:C administration increased Tnf, Il-6 and Il-10 protein in placenta after 3h (Mueller et al., 2019) , increased placental Il-6 mRNA after 3h (Wu et al., 2017) , and increased other cytokine mRNAs (e.g. Tnf Il-10) to a much lesser degree (Hsiao and Patterson, 2011) . We observed placental induction of Il-10 but not Tnf by poly I:C at 4h after administration. The slight discrepancy with respect to Tnf mRNA may simply reflect the different time point. We previously reported elevated placental Cxcl10 protein 6h after poly I:C administration (Openshaw et al., 2019) , and here we observed elevated Cxcl10 mRNA levels at 4h after administration.

The effects of resiquimod in placenta were greater than those observed with poly I:C for Il-6, Il-10 and Cxcl10. Induction of other immune mediators was detected after resiquimod administration, where no poly I:C effects were observed (e.g. Ccl5, Ccl11, Cxcl11, Tnf mRNAs). The data show that TLR7/8 stimulation can generate a powerful immune response in placental tissue in mice. It is of interest that human umbilical cord blood cells also appear more sensitive to resiquimod than to poly I:C, in terms of induction of IL-6, IL-10 and TNF (   ) suggesting that the same is true in human tissue.

From a mechanistic perspective, both a pro-inflammatory (IL-6 and TNF) and an anti-inflammatory (IL-10) response, as well as an anti-viral (CXCL10) response, have been triggered in the placenta. The more extensive response to resiquimod includes a series of chemokines -CXCL1 and CCL2 are particularly important for recruiting inflammatory monocytes, and CCL11 is an eosinophil attractant (Sokol and Luster, 2015) . hence resiquimod has induced the anticipated anti-viral reaction in the placenta. However, the extent to which these immune response mediators can access the foetal compartment is not clear in most cases (see below).

In foetal brain, it has been reported that protein levels of IL-1β, IL-6, IL-10 and Tnf were elevated at 3 or 6h after maternal poly I:C administration (Meyer et al., 2006) , while another study failed to detect any increase in brain levels of IL-6 or TNF 6h after maternal poly I:C administration (Abazyan et al., 2010) . Current concerns about the reproducibility of poly I:C administration have been noted above. Maternal LPS administration, though, elevates foetal brain TNF and IL-6 protein after 4h and 24h (Oskvig et al., 2012) . In principle, the origin of these cytokines could be from the maternal side of the placenta, but a small increase (< 2 fold) in Il-6 mRNA has also been detected in foetal brain 3h after poly I:C administration, which had normalised by 6h after administration (Wu et al., 2017) . We did not detect any elevations in foetal brain cytokine mRNAs at 4h after maternal poly I:C, despite the effects seen in maternal plasma and in placenta. It is possible that small effects of poly I:C on cytokine transcription in foetal brain do occur, but are very transient, and have resolved by 4h after drug administration. However, very low relative responses to TLR3 stimulation have also been noted in human foetal tissue (Stinson et al., 2019) . In contrast to the lack of effect of maternal poly I:C on foetal brain cytokines and chemokines, resiquimod produced a large (10-100 fold) stimulation of TNF Il-6, Il-10, Ccl2, Ccl5 and Cxcl10 expression (Figure 3 ). Substantial induction of Ccl11 and Cxcl1 mRNAs were also observed. Overall, it is clear from our data that maternal exposure to resiquimod has more substantial effects than poly I:C on the foetal CNS.

Comparing the placental and foetal brain responses, poly I:C up-regulated IL-6 and IL-10 expression in placenta, but not in brain, whereas resiquimod up-regulated these cytokines in both compartments. As noted above, there is evidence that many of the effects of MIA on the foetus (i.e. brain IL-6 and Cxcl10 induction) are mediated by maternal IL-6 acting on the placenta (Hsiao and Patterson, 2012; Wu et al., 2017) , and there is clear evidence that maternal IL-6 penetrates into the foetal compartment (Zaretsky et al., 2004; Dahlgren et al., 2006) . In this study, the fact that poly I:C increased maternal plasma and placental IL-6 expression, but did not affect all the mediators in the foetal brain affected by resiquimod (including IL-6 and Cxcl10) suggests that other mechanisms are also involved. Therefore, while both agents increased maternal plasma IL-6, our study suggests that not all effects on the foetal brain are mediated via maternal Il-6, and that there are qualitative differences in the foetal brain response to maternal poly I:C and resiquimod administration. One possibility to consider is that resiquimod can penetrate the placental barrier and infiltrate the foetal circulation and brain, while poly I:C cannot. There are no data available concerning the ability of resiquimod to cross the placenta in any species. However, if it can penetrate into the foetal compartment, that would usefully mirror the ability of some of the infectious agents most strongly associated with schizophrenia risk, such as Rubella and Toxoplasma Gondii, that do cross the placenta (Robbins et al., 2012) and affect the foetus directly.

There were some other interesting differences between the foetal brain response and the placental response. For example, Ccl2 expression was elevated by resiquimod in foetal brain but not in placenta. Clearly this cannot reflect different penetration/bioavailability between the two tissue compartments, as resiquimod must pass through the placenta to access the foetal brain. We suggest that the reason is that foetal brain Ccl2 expression is from a CNS-specific cell type rather than from immune cells, and specifically from astrocytes, which are present in the developing brain at E12.5 (Fox et al., 2004) . Indeed, it has been reported that Ccl2 in the brain is produced basally by astrocytes rather than microglia (Hayashi et al., 1995; Peterson et al., 2004) , and that TLR7 stimulation causes Ccl2 release from astrocytes but not from microglia (Butchi et al., 2010) . Thus, the Ccl2 mRNA induction may be demonstrating a direct or indirect action of resiquimod on foetal astrocytes.

The need to understand the consequences of maternal immune activation (MIA) with ss-virus mimetics becomes particularly important, considering that we have recently demonstrated that the microglial responses to stimulation of TLR3, TLR4 and TLR7 are very different (Kwon et al., 2021) . While a number of reports suggest microglial activation in foetal brain following MIA in rats or mice, (Prins et al., 2018; Murray et al., 2019; Ozaki et al., 2020) , there is evidence that maternal poly I:C administration does not evoke activation of foetal brain microglia (Smolders et al., 2015) . We have previously found that LPS, poly I:C and resiquimod produce differing responses in microglial cells in vitro (Kwon et al., 2021) , suggesting that distinct responses to these immune mimetics are also likely to be observed in foetal brain after MIA.

Resiquimod increased the expression of Aif1 mRNA (encoding the widely used immune cell/ monocyte/macrophage marker Iba1) (Ribeiro et al., 2013; Elmore et al., 2014; Bruttger et al., 2015) , consistent with either activation or proliferation of microglial cells. However, resiquimod decreased the expression of Tmem119 mRNA and Cx3cr1 mRNA, in foetal brain. Cx3cr1, like Iba1, is commonly used as an immune cell marker, identifying microglia, macrophages and monocytes (Harrison et al., 1998; Ginhoux et al., 2010; Mizutani et al., 2012) . Tmem119 expression has been recently characterised as being specific to microglia, and not expressed in macrophages or monocytes (Bennett et al., 2016) . However, its biological functions are not fully studied yet.

Microglia respond to immune stimulation with reduced Tmem119 expression (Bennett et al., 2016; Sousa et al., 2018; Jordão et al., 2019; Ronning et al., 2019) and reduced Cx3cr1 expression (Boddeke et al., 1999; Wynne et al., 2010; Haimon et al., 2018; Sousa et al., 2018; Yosef et al., 2018) . In fact, increased expression of Ccl5 and Aif1, and decreased expression of Tmem119 and Cx3cr1, appears to be a highly-characteristic signature of microglial activation (Butovsky et al., 2014; Zhang et al., 2019) . Our data therefore are strongly suggestive of microglial activation in the foetal CNS, following maternal TLR7/8, but not TLR3, stimulation.

The reason for the decreased Ccr2 expression after MIA is less clear. CCR2 is traditionally viewed as a monocyte/macrophage marker, not expressed in microglial cells (Prinz et al., 2011; Mizutani et al., 2012; Greter et al., 2015) . However, the decreased expression of Ccr2 mRNA after MIA is difficult to reconcile with altered monocyte presence in the foetal brain. There is recent evidence that microglia at E12-14 transiently express low levels of Ccr2 (Kierdorf et al., 2013; Chen et al., 2020) , which then becomes undetectable later in development. The Ccr2 signal in the foetal brain at E12.5 may therefore derive from microglial cells. TLR4 activation by LPS reportedly decreases CCR2 expression in monocytes (Sica et al., 1997; Weber et al., 1999; Parker et al., 2004; Heesen et al., 2006; Sousa et al., 2018) . We favour the interpretation that the diminished Ccr2 mRNA expression after poly I:C and resiquimod is a similar phenomenon reflecting immune activation, but in developing microglia.

In contrast to Ccr2 and Cx3cr1, Ly6c protein levels are thought to be unchanged by immune stimuli (Jordão et al., 2019; Ronning et al., 2019) . Like Ccr2, Ly6c2 is viewed as a specific monocyte/macrophage marker, not present in microglia, and this indeed appears to be the case whatever the stage of microglial development (Butovsky et al., 2014; Bowman et al., 2016; DePaula-Silva et al., 2019; Jordão et al., 2019; Ronning et al., 2019) . The lack of change in Ly6c2 expression that we observe in foetal brain after MIA suggests that there is no overt infiltration of the foetal brain by monocytes.

The use of poly I:C administration to pregnant rats or mice, as a means of modelling the increased risk for schizophrenia caused by in utero exposure to infection, has become widespread (Zuckerman et al., 2003; Meyer et al., 2005; Estes and McAllister, 2016) . Recently, however, it has become clear that variability in the characteristics of the poly I:C used are a significant issue (Kowash et al., 2019; Mueller et al., 2019) . We propose that the use of resiquimod as an alternative may offer advantages in terms of reproducibility between laboratories. Furthermore, resiquimod has some conceptual advantages over poly I:C, specifically in relation to modelling schizophrenia risk. Increased risk of schizophrenia is linked with in utero exposure not only to influenza and rubella exposure (Mednick et al., 1988; Brown et al., 2001; Brown, 2011 Brown, , 2012 Canetta and Brown, 2012) , (both ss-viruses), but also to bacterial (Sorensen et al., 2009; Younga H. Lee et al., 2020) and parasitic (Toxoplasma Gondii) infections (Alan S. Brown et al., 2005; Brown, 2012) , suggesting that the exact nature of the infectious agent is not a critical factor. However, the epidemiological evidence linking schizophrenia risk to maternal infection specifically by ds-viruses (e.g CMV, HSV-1) is weak (Khandaker et al., 2013) . Conversely, the evidence for maternal ss virus infection as a risk factor is strong. Furthermore, Toxoplasma Gondii also activates TLR7 (Yarovinsky and Sher, 2006) , as do many bacteria (Mancuso et al., 2009) . It is also clear that the nature of the immune response in the brain is different to different infectious agents (Olson and Miller, 2004; Kwon et al., 2021) .

Hence, until there is a more complete understanding of the mechanisms linking in utero exposure to infection with disease risk, it may be prudent to consider the use of a bacterial or ss-virus mimetic, for rodent models relating to schizophrenia. Furthermore, since resiquimod, in contrast to poly I:C, is likely to penetrate the placenta and enter the foetal compartment, it may be a much better model for agents such as influenza (Raj et al., 2014) , rubella (Leung et al., 2019) and Toxoplasma Gondii (Robbins et al., 2012) , which can also cross the placenta. A direct action of the infectious agent on the foetal brain may be essential for the disease-relevant mechanisms to be triggered. We therefore put resiquimod forward as a useful agent for modelling schizophrenia environmental risk mechanisms in rodents, to reduce experimental variability and maximise construct validity.

List of abbreviations ds -double-stranded LPS -lipopolysaccharide MFI -mean fluorescence intensity poly I:C -polyinosinic: polycytidylic acid ss -single-stranded TLR -toll like receptor Declarations Ethics approval and consent to participate In vivo experiments were performed according to Home Office (UK) regulations, and were approved by the University of Glasgow Ethical Review Board. Consent for publication Not applicable Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

The authors have no conflicts of interest to declare Funding

The research leading to these results received funding from the Wellcome Trust under Grant reference 104025/Z/14/Z Authors' contributions JK performed all of the experiments and contributed to an initial draft of the paper. MS and AM provided important practical contributions to many of the experiments. JC and BM supervised the study, and provided advice on data analysis and interpretation. BM conceived the study and wrote most of the manuscript.

Prenatal Interaction of Mutant DISC1 and Immune Activation Produces Adult Psychopathology

TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs

The fetal origins of mental illness

Maternal Exposure to Toxoplasmosis and Risk of Schizophrenia in Adult Offspring

Combined Action of Nucleic Acid-Sensing Toll-like Receptors and TLR11/TLR12

Heterodimers Imparts Resistance to Toxoplasma gondii in Mice

Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology

New tools for studying microglia in the mouse and human CNS

Functional expression of the fractalkine (CX3C) receptor and its regulation by lipopolysaccharide in rat microglia

Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies

Bead-based multiplex immuno-assays for cytokines, chemokines, growth factors and other analytes: Median fluorescence intensities versus their derived absolute concentration values for statistical analysis

The Statistical Value of Raw Fluorescence Signal in Luminex xMAP Based Multiplex Immunoassays

Prenatal Infection as a Risk Factor for Schizophrenia

The environment and susceptibility to schizophrenia

Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism

Maternal Immune Activation and Neuropsychiatric Illness: A Translational Research Perspective

No Evidence of Relation Between Maternal Exposure to Herpes Simplex Virus Type 2 and Risk of Schizophrenia?

Prenatal rubella, premorbid abnormalities, and adult schizophrenia

Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system

Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia

Identification of a unique TGF-beta dependent molecular and functional signature in microglia

Fate mapping via CCR2-CreER mice reveals monocyte-to-microglia transition in development and neonatal stroke

Selection and evaluation of reference genes for analysis of mouse (Mus musculus) sex-dimorphic brain development

Interleukin-6 in the maternal circulation reaches the rat fetus in mid-gestation

Differential transcriptional profiles identify microglial-and macrophage-specific gene markers expressed during virus-induced neuroinflammation

TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury

Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain

Maternal immune activation: Implications for neuropsychiatric disorders

Developmental expression of glial fibrillary acidic protein mRNA in mouse forebrain germinal zonesimplications for stem cell biology

Sex differences in prefrontal cortex microglia morphology: Impact of a two-hit model of adversity throughout development

Fate mapping analysis reveals that adult microglia derive from primitive macrophages

Microglia Versus Myeloid Cell Nomenclature during Brain Inflammation

Re-evaluating microglia expression profiles using RiboTag and cell isolation strategies

Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia

Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells

Human Endotoxemia Induces Down-Regulation of Monocyte CC Chemokine Receptor 2

Speciesspecific Regulation of Toll-like Receptor 3 Genes in Men and Mice

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

Activation of the maternal immune system induces endocrine changes in the placenta via IL-6

Placental regulation of maternal-fetal interactions and brain development

Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers

Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation

Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies

Microglia emerge from erythromyeloid precursors via Pu.1-and Irf8-dependent pathways

Poly(I:C) source, molecular weight and endotoxin contamination affect dam and prenatal outcomes, implications for models of maternal immune activation

Differential Effects of Toll-Like Receptor Activation and Differential Mediation by MAP Kinases of Immune Responses in Microglial Cells

Rubella (German measles) revisited

Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells

TLR3, TRIF, and Caspase 8 Determine Double-Stranded RNA-Induced Epithelial Cell Death and Survival In Vivo

TLR7-mediated skin inflammation remotely triggers chemokine expression and leukocyte accumulation in the brain

Adult Schizophrenia Following Prenatal Exposure to an Influenza Epidemic

Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems

In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders

Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia

The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology

Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance

Sexdependent neurobiological features of prenatal immune activation via TLR7

The Fractalkine Receptor but Not CCR2 Is Present on Microglia from Embryonic Development throughout Adulthood

Early Infections of Toxoplasma gondii and the Later Development of Schizophrenia

Influence of poly(I:C) variability on thermoregulation, immune responses and pregnancy outcomes in mouse models of maternal immune activation

Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects

Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs

JNK signalling mediates aspects of maternal immune activation: importance of maternal genotype in relation to schizophrenia risk

Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response

Chapter 6 -Congenital and perinatal infections

Maternal immune activation induces sustained changes in fetal microglia motility

Toll-Like Receptor (TLR)2 and TLR4 Agonists Regulate CCR Expression in Human Monocytic Cells

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes

MCP-1 and CCR2 Contribute to Non-Lymphocyte-Mediated Brain Disease Induced by Fr98 Polytropic Retrovirus Infection in Mice: Role for Astrocytes in Retroviral Neuropathogenesis

Microglia, the missing link between maternal immunity and fetal neurodevelopment

Heterogeneity of CNS myeloid cells and their roles in neurodegeneration

Influenza, Immune System, and Pregnancy

Effects of influenza on pregnant women and infants

Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine

Cytokine Concentrations Measured by Multiplex Assays in Canine Peripheral Blood Samples

Tissue barriers of the human placenta to infection with Toxoplasma gondii

Molecular profiling of resident and infiltrating mononuclear phagocytes during rapid adult retinal degeneration using single-cell RNA sequencing

The Small Antitumoral Immune Response Modifier Imiquimod Interacts with Adenosine Receptor Signaling in a TLR7-and TLR8-Independent Fashion

Bacterial Lipopolysaccharide Rapidly Inhibits Expression of C-C Chemokine Receptors in Human Monocytes

Maternal Leukemia Inhibitory Factor (LIF) Promotes Fetal Neurogenesis via a LIF-ACTH-LIF Signaling Relay Pathway

IFN-α Regulates TLR-Dependent Gene Expression of IFN-α, IFN-β, IL-28, and IL-29

Maternal immune activation evoked by polyinosinic:polycytidylic acid does not evoke microglial cell activation in the embryo

The Chemokine System in Innate Immunity

Association Between Prenatal Exposure to Bacterial Infection and Risk of Schizophrenia

Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures

Placental and intra-amniotic inflammation are associated with altered fetal immune responses at birth

TLR and NOD2 Ligands Induce Cell Proliferation in the Rat Intact Spinal Cord

Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner

Peripheral inflammation is associated with remote global gene expression changes in the brain

Microglia, complement and schizophrenia

Late gestation modulation of fetal glucocorticoid effects requires the receptor for leukemia inhibitory factor: an observational study

Downregulation by tumor necrosis factor-alpha of monocyte CCR2 expression and monocyte chemotactic protein-1-induced transendothelial migration is antagonized by oxidized low-density lipoprotein: a potential mechanism of monocyte retention in atherosclerotic lesions

Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase Amediated GLI phosphorylation

Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro

The placental interleukin-6 signaling controls fetal brain development and behavior

Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge

Innate immunity to Toxoplasma gondii infection

Toll-like receptor recognition of Toxoplasma gondii

The phenotypic and functional properties of mouse yolk-sac-derived embryonic macrophages

Maternal Bacterial Infection During Pregnancy and Offspring Risk of Psychotic Disorders: Variation by Severity of Infection and Offspring Sex

Transfer of inflammatory cytokines across the placenta

NG2 glia regulate brain innate immunity via TGF-β2/TGFBR2 axis

Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia